Navigation Links
Avastin Shows No Benefit Against Early Stage Colon Cancer
Date:5/30/2009

'Disappointing' results may yet be reversed with longer-term study, researchers say

SATURDAY, May 30 (HealthDay News) -- The cancer drug Avastin, widely used for lung, breast and metastatic colorectal cancers, appears ineffective for patients with early stage colon cancer, a result the trial's lead author called "disappointing."

"There's no sense of building up a false sense of anticipation and drama. We failed to provide patients with a novel intervention which would increase the cure rate," said that author, Dr. Norman Wolmark, chairman of the department of human oncology at Allegheny General Hospital in Pittsburgh and chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), which conducted the study.

But at a news conference, held Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla., Wolmark pressed the point that Avastin (bevacizumab) did bring an improvement while it was given to patients. However, this benefit vanished once patients stopped taking the drug.

"The hoped-for endpoints of the trial -- to increase the cure rate of early stage colon cancer -- were simply not met," he said. "Having said that, it is clear that there was a statistically significant transient benefit in disease-free survival during the time that [Avastin] was given, so it was effective. But, that efficacy disappeared after the year that it was given."

At one year, there was an absolute difference in disease-free survival of only 3.6 percent in favor of Avastin. And the jury may still be out on whether or not Avastin's benefits might last if patients receive it for a longer period of time. "Clearly, strong consideration should be given to clinical trials that use [Avastin] for periods of time beyond the one year that was used in this protocol," Wolmark said.

The trial, a large one involving 2,710 patients from 245 institutions, was funded by the U.S.
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration
2. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
3. Avastin effective at delaying brain tumor progression in recurrent disease
4. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
5. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
6. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
7. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
8. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
9. Avastin Added to Chemo Helps Women With Advanced Cancer
10. Off-Label Avastin Use for Wet Macular Degeneration
11. FDA OKs Avastin for Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Shows No Benefit Against Early Stage Colon Cancer
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... 2014 Recently, BambooIndustry.com, one of the ... new range of bamboo deckings . Moreover, the ... items; they are now available at deeply discounted rates. ... is hard to overstate the significance of online business ... online services. The company’s workers are striving to deliver ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 20, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, GoDaddy and HostMonster are the best ... (Virtual Private Server) is the method of partitioning ... of which has the appearance and capabilities of ... why the site pays close attention to VPS ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... 12 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... of Suzanne D. Snapper to succeed soon-to-be-retiring CFO ... , Ms. Snapper has been serving as ...
... MedApps, Enabling Mobile Wireless Technology Links Patients, Care ... Retail Off-the-Shelf Medical DevicesSCOTTSDALE, Ariz., May 12 ... provide a new, convenient and cost effective solution ... health record. MedApps, HealthPAL is a unique solution ...
... Carbon Footprint at DaVita,s Six Corporate Business OfficesEL SEGUNDO, ... DVA ), a leading provider of kidney care services ... announced that the company is the first FORTUNE 500 ... (EPA) Green Power Partnership program. Joining this program is ...
... 12 Occlutech, the leading European,developer of septum occluders, today ... generation ASD and PFO occluders, the Figulla Flex. , ... encompass a new innovative,delivery system, making the use of a ... the ability of the delivery,system to allow a 45 degree ...
... will present technology and admissions educational sessions for ACHCA members ... ... 12, 2009 --Patient Placement Systems, the leading provider of automated ... will exhibit and present two sessions at the American College ...
... love its usability & CCHIT recognizes its functionality; CureMD EHR ... ... New York, NY (PRWEB) May 12, 2009 -- The Certification ... EHR v10 complies with updated interoperability requirements, is a conditionally ...
Cached Medicine News:Health News:The Ensign Group Announces the Retirement of CFO Alan J. Norman; Names Suzanne D. Snapper as New Chief Financial Officer 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 3Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 2Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 3Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 2Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 3Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 2Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 3
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... April 12, 2011 Visual Healthcare Corp. (the "Company") (NASDAQ ... Chinese based adaptation of the information technology grid that its ... This project has been launched in response to requests from ... experts responding to Chinese government resolve to create a major ...
... 2011 Southern Home Medical Equipment, Inc. (PINKSHEETS: ... professionals and equipment to medical institutions, announced today ... for fiscal year 2010 have been restated to ... Staffing. In a previous announcement dated ...
Cached Medicine Technology:Visual Healthcare to Support Chinese Clinical Trials 2Visual Healthcare to Support Chinese Clinical Trials 3Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: